17.11.2019 18:29:34
|
AstraZeneca Announces New Data From Phase III DAPA-HF Trial
(RTTNews) - AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that FARXIGA reduced the risk of the primary composite outcome of worsening heart failure (HF), defined as hospitalization or an urgent visit, or death from cardiovascular (CV) causes versus placebo, when added to standard of care.
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of HF in patients with reduced ejection fraction (HFrEF), with and without type 2 diabetes (T2D).
The new analyses showed the consistency of these results across patient subgroups with and without T2D, an early onset of effects, and improvement in patient-reported outcomes of HF-related health status.
Across all five analyses, FARXIGA showed improvements versus placebo in the worsening or progression of the disease and improved patient-reported symptoms and quality of life.
In a separate press release, AstraZeneca said that New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that BRILINTA monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT) over 12 months in high-risk patients with non-ST elevation acute coronary syndromes (NSTE-ACS).

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
14.03.25 |
Zuversicht in New York: NASDAQ 100 zum Ende des Freitagshandels im Plus (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Freitagnachmittag fester (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 am Freitagmittag stärker (finanzen.at) | |
14.03.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Start des Freitagshandels Zuschläge (finanzen.at) | |
13.03.25 |
NASDAQ-Handel NASDAQ 100 schlussendlich leichter (finanzen.at) | |
13.03.25 |
Verluste in New York: NASDAQ 100 verbucht nachmittags Abschläge (finanzen.at) | |
13.03.25 |
Schwacher Handel in New York: NASDAQ 100 im Minus (finanzen.at) | |
13.03.25 |
NASDAQ 100 aktuell: NASDAQ 100 verliert zum Start des Donnerstagshandels (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 70,50 | 0,00% |
|